Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Marinus (MRNS) Stock Price & Analysis
1,096 Followers
MRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $11.26
Previous Close$1.44
Volume1.35M
Average Volume (3M)1.72M
Market Cap
$78.69M
Enterprise Value$1.37M
Total Cash (Recent Filing)$150.29M
Total Debt (Recent Filing)$72.97M
Price to Earnings (P/E)-0.5
Beta1.19
Next Earnings
May 09, 2024EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.63
Shares Outstanding54,642,580
10 Day Avg. Volume8,428,969
30 Day Avg. Volume1,722,095
Standard Deviation0.26
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)4.69
Price to Sales (P/S)10.94
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.05
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$10.56Price Target Upside643.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Marinus News
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialThe company could still be an attractive acquisition target, potentially leading to a higher valuation.
Clinical Trial ProgressAn independent data committee recommended the continuation of the trial, indicating positive progress.
Market OpportunitySignificant market opportunity anticipated for Marinus, with commercial potential exceeding $600M.
Bears Say
Clinical Trial ResultsPhase 3 RAISE study of ganaxolone in refractory status epilepticus did not meet the pre-defined stopping criteria at the interim analysis, casting doubts on the drug's efficacy.
Company's Financial HealthMarinus is reviewing cost-cutting measures to support their cash balance due to a bleak future for IV ganaxolone, signaling concerns over the company's financial stability.
Financial ForecastAnalyst lowers the risk-adjusted, DCF-derived price target from $15 to $12, reflecting significantly reduced expectations for the commercial success of IV ganaxolone.
---
Ownership Overview
34.04% Insiders
21.87% Mutual Funds
10.41% Other Institutional Investors
33.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNS FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $1.11 and its highest was $11.26 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on Mar 05, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.623 by -$0.117.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -$0.66.
How many shares outstanding does Marinus have?
Marinus has 54,642,580 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.623. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is GMT Capital Corp. It holds Marinus’s shares valued at 19M.
---
Marinus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.56 (643.66% Upside)
$10.56 (643.66% Upside)
Blogger Sentiment
Bullish
MRNS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 137.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $214.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.79%
12-Months-Change
Fundamentals
Return on Equity
-213.02%
Trailing 12-Months
Asset Growth
-34.14%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Earnings Call
Q4 2024
0:00 / 0:00
---
MRNS Stock 12 Months Forecast
Average Price Target
$10.56
▲(643.66% Upside)
Technical Analysis
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
16/34 ratings generated profit
1 Year Average Return
+6.29%
reiterated a buy rating 12 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +6.29% per trade.
---